Immunotherapy duo takes on rare sarcoma in new trial

NCT ID NCT04095208

Completed Disease control Sponsor: Institut Bergonié Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tested whether combining two immunotherapy drugs, nivolumab and relatlimab, can help people with advanced or metastatic soft-tissue sarcoma. The study enrolled 68 adults whose tumors had a specific immune structure. Researchers measured how many patients had their cancer stop growing or shrink over six months. The goal is to find a new way to control this rare cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: nivolumab and relatlimab (immunotherapy drugs)
What this could lead to: If it works, this could offer a new treatment option for people with advanced soft-tissue sarcoma, potentially slowing the disease.
What could go wrong: This is a small, early-phase trial with only 68 participants. The drugs may not work for all sarcoma types, and side effects from immunotherapy can be serious.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer neoplasm Neoplasm Metastasis sarcoma soft tissue sarcoma Tertiary Lymphoid Structures

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED CANCER SOFT TISSUE SARCOMA ADULT

Contacts and locations

Locations

Centre Léon Bérard

Lyon, 69000, France
Hôpital Cochin

Paris, 75014, France
Institut Bergonié

Bordeaux, 33000, France
Institut Gustave Roussy

Villejuif, 94805, France
Institut de Cancérologie de l'Ouest - Site René Gauducheau

Nantes, 44805, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.